Rapport Therapeutics, Inc.
Rapport Therapeutics (RAPP) reached a 52-week high of $52.83. Its lead drug, RAP-219, entered Phase 3 trials for focal onset seizures, with strong clinical data showing sustained seizure reductions. The company reported a Q2 2026 net loss of $56.6M, up from $26.7M a year ago, with cash reserves of $436.1M. RAPP closed at $52.50, up 2.60%.
Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
Ceesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 2 news stories mentioning RAPP (Rapport Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RAPP coverage spans insider activity, financial news and technology.
In the last 30 days, RAPP insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($5.9M). The most active reporter was Ceesay Abraham, Chief Executive Officer, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Phase 3 entry suggests higher probability of approval, likely supporting near‑term price appreciation.
Advancing late‑stage trial supports valuation uplift.
The insider sale modestly increases supply and may signal limited confidence, but the amount is small relative to market cap.
Insider sale may signal reduced confidence, potentially pressuring the stock short term.
This is a routine insider-sale disclosure, not a new operating or regulatory catalyst, but it can slightly affect near-term sentiment.
alphai scores every news story that mentions RAPP with an AI model for sentiment and relevance, and aggregates insider trades from Rapport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rapport Therapeutics (RAPP) reached a 52-week high of $52.83. Its lead drug, RAP-219, entered Phase 3 trials for focal onset seizures, with strong clinical data showing sustained seizure reductions. The company reported a Q2 2026 net loss of $56.6M, up from $26.7M a year ago, with cash reserves of $436.1M. RAPP closed at $52.50, up 2.60%.
2 min readFive biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD
3 min readCeesay Abraham (Chief Executive Officer) sold 18,921 shares of Rapport Therapeutics, Inc. (RAPP) at $49.57 ($0.94M total) on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readYeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $50.47 ($50.00–$51.06, $2.53M total) across 3 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readCeesay Abraham (Chief Executive Officer) sold 51,499 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $47.25 ($45.97–$48.62, $2.43M total) across 5 trades over 2026-08-10 to 2026-08-11 under a Rule 10b5-1 trading plan.
2 min readRapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results
6 min readRapport Therapeutics COO Cheryl Gault sold 10,000 shares of RAPP stock for about $416,000 in open-market trades on June 30, 2026, per an SEC Form 4. The sale reduced her direct holdings by 6.25% to 149,914 shares, worth about $5.9 million. The article notes RAPP shares were up 223.67% year over year as of July 1, 2026.
6 min readRapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0002012593 0002012593 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readThird Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at $40.05 ($0.74M total) on 2026-05-26 under a Rule 10b5-1 trading plan.
2 min readRapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, sold 20,225 shares of the company's common stock for over $808,000 on April 17, 2026, through a pre-arranged trading plan. Despite the sale, the company's stock has seen a significant annual increase, though it is currently considered overvalued according to InvestingPro. Meanwhile, Rapport Therapeutics recently announced positive Phase 2a trial results for its epilepsy drug RAP-219, leading to accelerated Phase 3 trials and reiterated "Buy" ratings from several analysts.
3 min read